{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-22-000208","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.580141+00:00","generated_at":"2026-06-22T01:26:41.033896+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeiGene Q3 product revenue up 82% to $349.5M; BRUKINSA sales +136%; net loss widens","bullets":["Product revenue $349.5M (+82% YoY); BRUKINSA global sales $155.5M (+136%), U.S. $108.1M (+221%).","Net loss $557.6M ($0.41/share) vs $438.1M loss prior year; includes $125.6M FX losses.","Cash $5.1B (down from $6.6B); cash used in operations $561.9M.","BRUKINSA achieved superior PFS vs ibrutinib in ALPINE final analysis; EC approved MZL; CHMP positive for CLL.","Tislelizumab China sales $128.2M (+67%); HCC trial met OS endpoint vs sorafenib."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-22-000208","json":"https://secwatch.observer/filing/0001651308-22-000208.json","markdown":"https://secwatch.observer/filing/0001651308-22-000208.md","text":"https://secwatch.observer/filing/0001651308-22-000208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/0001651308-22-000208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/bgne-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:26:41.033896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5ae44b959625c050bfef089b106a53944a8ff85","claim":"BeOne Medicines Ltd. reported the three months ended September 30, 2022 results: revenue $387.6 million, net income net loss of $557.6 million.","evidence_excerpt":"into the U.S. dollar negatively impacted ending cash by $62.7 million in the three months ended September 30, 2022. Revenue for the three months ended September 30, 2022 was $387.6 million, compared to $206.4 million in the same period of 2021. • Product revenue totaled $349.5 million for the three months ended September 30, 2022, compared to $192.5 million in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/0001651308-22-000208-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$387.6 million"},{"label":"Net income","value":"net loss of $557.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}